IP Library Granted Patent US 8,084,248
Granted Patent B2
US 8,084,248 · App. 11/606,700 · Granted Dec 27, 2011

Reverse genetic system for rift valley fever virus and uses thereof

Assignee: The Board of Regents of The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,248
App. No.
11/606,700
Granted
Dec 27, 2011
Kind
B2
Abstract

The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses .

Claims (16)

1. A reverse genetic composition for a Phlebovirus , comprising:

at least one anti-viral sense RNA expression plasmid that encodes a non-viral gene inserted in place of a non-structural protein (NSs) open reading frame (ORF) in the Phlebovirus Small (S) segment, such that said non-structural protein (NSs) open reading frame (ORF) for said Phlebovirus is deleted but the N gene is not deleted;

at least one anti-viral sense RNA expression plasmid that encodes a Phlebovirus Large (L) segment;

at least one anti-viral sense RNA expression plasmid that encodes a Phlebovirus Medium (M) segment;

at least one viral protein expression plasmid that expresses a Phlebovirus L protein;

at least one viral protein expression plasmid that expresses a Phlebovirus N protein; and

at least one viral protein expression plasmid that expresses Phlebovirus envelope proteins.

2. The composition of claim 1 , wherein the non-viral gene expresses a reporter protein.

3. The composition of claim 2 , wherein the reporter protein is a Renilla luciferase or a green fluorescent protein.

4. The composition of claim 1 , wherein the Phlebovirus is a Rift Valley fever virus, a Toscana virus, a Sandfly fever virus or a Punta Toro virus.

5. The composition of claim 4 , wherein the Rift Valley fever virus strain is selected from the group consisting of MP-12, modified MP-12, ZH501, ZH548, SA75, and SPB 9800523.

6. An isolated cell comprising and expressing the plasmids of the reverse genetic system of claim 1 .

7. The isolated cell of claim 6 , wherein the host cell is a T7 polymerase expressing cell.

8. The isolated cell of claim 7 , wherein the host cell is a BHK cell.

9. The composition of claim 2 , wherein the M-segment encoded by anti-viral sense RNA expression plasmids comprise partial deletions in the sequence encoding the L segment, wherein said partial deletion does not abolish the replication of said Phlebovirus in host cells.

10. The composition of claim 2 , wherein the MM segment encoded by anti-viral sense RNA expression plasmids comprise partial deletions in the sequence encoding the M segment, wherein said partial deletion does not abolish the replication of said Phlebovirus in host cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 21, 2017
From: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042931/0480 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2012
From: MAKINO, SHINJI; IKEGAMI, TETSURO; PETERS, CLARENCE J.; WON, SUNGYONG
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 028979/0012 →
Continuity (2)
Provisional Application 60740853 · Nov 30, 2005
Related Publication 20070122431A1 · May 31, 2007